Mount Sinai Hospital has successfully performed New York City’s first procedure using the HYDROS™ Robotic System, an advanced technology designed to treat benign prostatic hyperplasia (BPH).
Image Credit: crystal light/Shutterstock.com
This minimally invasive approach offers new hope for individuals experiencing BPH symptoms such as frequent urination, incomplete bladder emptying, and nighttime urgency.
The hospital’s urologists recently completed the first three procedures using this technology, with all patients responding well and being discharged the following day.
This technology provides a much-needed option for men dealing with the burdens of BPH. What makes HYDROS™ stand out is how it combines advanced imaging, robotic precision, and a heat-free approach to tissue removal, all while preserving crucial functions like continence and sexual health.
Steven A. Kaplan, MD, Professor, Icahn School of Medicine, Mount Sinai Hospital
He is also the Director of the Men’s Wellness Program at Mount Sinai Health System.
BPH is one of the most common conditions affecting older men, impacting 80 to 90 percent of those over 70 and more than 50 percent of men over 60. Although it is not cancerous, BPH can greatly diminish quality of life, causing discomfort, frustration, and lifestyle disruptions.
The HYDROS™ system builds upon existing surgical treatments like transurethral resection of the prostate (TURP) and laser therapies with key advancements. Its FirstAssist AI™ software leverages ultrasound-based image recognition to identify essential anatomical structures, enabling AI-driven treatment planning tailored to each patient’s prostate anatomy.
Additionally, the system integrates enhanced ultrasound imaging with digital cystoscopy, providing surgeons with a comprehensive, multidimensional view of the prostate. This improved visualization enhances precision during surgery and aids in more effective treatment planning.
A key feature of HYDROS™ is its robotic-assisted, heat-free waterjet technology for tissue resection. This approach effectively removes obstructive tissue while preserving crucial anatomical structures, significantly reducing the risk of complications such as incontinence or erectile dysfunction.
The system also streamlines surgical procedures with an integrated setup, an adjustable touchscreen for improved ergonomics, and intuitive software that guides surgeons step-by-step.
By reducing tissue damage and minimizing side effects, HYDROS™ offers a more precise and patient-friendly alternative to traditional treatments.
To expand access to this technology, Mount Sinai is prioritizing training for its urology team. Dr. Kaplan, who has performed over 400 aquablation treatments using an earlier model, recently completed advanced HYDROS™ training. He and other Mount Sinai surgeons will continue performing these procedures in the coming months.
Kaplan added, “This new technology is part of our commitment to delivering the most advanced and patient-centered care. The positive outcomes we have seen so far are a testament to the potential of HYDROS to redefine how we approach BPH treatment.”
With this milestone, Mount Sinai strengthens its leadership in robotic-assisted surgery. The team will closely monitor patient outcomes, contributing to ongoing research on HYDROS™ and its benefits for men with BPH.
PROCEPT BioRobotics® Corporation’s HYDROS™ Robotic System received FDA 510(k) clearance on August 21, 2024.